Ornithogalum Umbellatum Whole

Dosage for Ornithogalum Umbellatum Whole is highly individualized and must be determined by a specialist based on the patient's sensitivity levels, as determined by skin testing or in vitro (blood) testing.

Diagnostic Testing Dosage

• Prick-Puncture Test: Usually, one drop of the 1:10 or 1:20 w/v concentrate is applied to the skin. A sterile lancet is used to prick the skin through the drop. A positive control (histamine) and negative control (saline) are used for comparison.
• Intradermal Test: If the prick test is negative but clinical suspicion remains high, a 1:100 to 1:1000 w/v dilution may be injected intradermally (0.02 to 0.05 mL) to create a small bleb.

Immunotherapy Dosage

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution). Injections are usually given 1-2 times per week, with the dose increasing by 50% to 100% each time, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'Maintenance Dose' is reached (the highest dose tolerated by the patient that provides symptomatic relief, often 0.5 mL of a 1:10 or 1:20 w/v concentrate), the frequency of injections is decreased to once every 2 to 4 weeks.

Ornithogalum Umbellatum Whole is generally considered safe for use in children, provided they are old enough to cooperate with the testing and injection procedure (typically 5 years and older). Dosage is generally similar to adult dosing but must be approached with greater caution due to the smaller body mass and potential for more rapid systemic absorption. There is no established safety for children under the age of 2.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the protein components are naturally degraded. However, the patient's overall health status should be stable before administration.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The extract does not undergo significant hepatic metabolism.

Elderly Patients

Elderly patients may have a higher prevalence of comorbid conditions (e.g., cardiovascular disease) that could make a systemic reaction more dangerous. Lower starting doses and slower escalation may be considered by the healthcare provider.

Ornithogalum Umbellatum Whole extract is administered exclusively by a healthcare professional in a clinical setting.

• Preparation: The vial should be inspected for particulate matter or discoloration before use. It should be kept refrigerated at 2°C to 8°C (36°F to 46°F).
• Administration: Injections for immunotherapy are given subcutaneously, usually in the posterior aspect of the upper arm. The site should be rotated between the left and right arms to minimize local tissue irritation.
• Observation: Patients MUST remain in the medical office for at least 30 minutes following any injection to monitor for signs of a systemic allergic reaction (anaphylaxis).

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.

• 1-2 weeks late: Usually, the same dose can be given.
• 3-4 weeks late: The dose may be reduced to the previous tolerated level.
• Over 4 weeks late: The healthcare provider may need to restart the build-up phase from a much lower concentration.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. This most commonly occurs due to a dosing error or a rapid increase in potency when switching to a new vial.

• Signs: Large local swelling, hives, wheezing, throat tightness, or a drop in blood pressure.
• Emergency Measures: Administration of Epinephrine (1:1000) is the primary treatment. Antihistamines, corticosteroids, and oxygen may also be required. Emergency medical services must be contacted immediately if a systemic reaction occurs.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your doctor if you have had a recent illness or a change in your other medications before receiving an injection.

Most patients receiving Ornithogalum Umbellatum Whole will experience some form of local reaction at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A pink or red area around the injection site is very common. It usually appears within minutes and resolves within 24 hours.
• Swelling (Wheal): A small, raised bump at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal local reaction.
• Itching (Pruritus): Localized itching at the site of injection or skin test is expected as the body reacts to the allergen.
• Tenderness: The area may feel slightly sore or warm to the touch for several hours after the procedure.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. These can be painful and may last for 2-3 days. While not life-threatening, an LLR often necessitates a dosage adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy session.
• Mild Nasal Congestion: A slight increase in allergy symptoms (sneezing, runny nose) may occur shortly after the injection.

• Generalized Hives (Urticaria): Itchy welts appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Granuloma: A small, hard knot under the skin at the injection site that may take weeks or months to disappear.

> Warning: Stop taking Ornithogalum Umbellatum Whole and call your doctor immediately if you experience any of these symptoms of anaphylaxis:

• Respiratory Distress: Wheezing, shortness of breath, or a persistent cough.
• Throat Tightness: A feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing.
• Cardiovascular Collapse: Rapid or weak pulse, dizziness, lightheadedness, or fainting (syncope).
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after an injection.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term detrimental effects associated with the proper use of Ornithogalum Umbellatum Whole. In fact, the 'long-term effect' sought is a permanent or semi-permanent reduction in allergic sensitivity. However, repeated injections in the same site without rotation can lead to localized skin thickening or changes in fat distribution (lipodystrophy), though this is rare with subcutaneous allergy shots.

While Ornithogalum Umbellatum Whole may not have a specific individual black box warning, the entire class of allergenic extracts carries a general warning regarding the risk of severe systemic reactions.

Summary of Class Warning:

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Extracts should only be administered in a facility equipped to treat anaphylaxis.
• Patients with unstable or severe asthma are at a higher risk for fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.

Report any unusual symptoms to your healthcare provider. Even a 'delayed' reaction occurring several hours after you leave the clinic should be reported before your next scheduled dose.

Ornithogalum Umbellatum Whole is a potent biological product. Safety is dependent on accurate dosing and the immediate availability of emergency medical care. Patients must be communicative with their providers regarding any changes in their health status, including new medications, pregnancy, or respiratory infections.

As of 2026, the FDA-mandated class warning for non-standardized allergenic extracts states that these products can cause anaphylaxis, which may be fatal. Because of this risk, the following must be strictly observed:

1. 1Supervision: Administration must occur under the supervision of a physician.
2. 2Observation: A 30-minute post-injection wait time is mandatory.
3. 3Emergency Equipment: Oxygen, epinephrine, and airway management tools must be on-site.

• Allergic Reactions / Anaphylaxis Risk: The risk is highest during the build-up phase or when switching to a new vial of extract. Patients with a history of high sensitivity (e.g., very large reactions on skin tests) must be dosed with extreme caution.
• Asthma Status: Patients with poorly controlled asthma (FEV1 < 80% of predicted) should not receive immunotherapy injections until their asthma is stabilized. A respiratory infection can also lower the threshold for a systemic reaction.
• Epinephrine Preparedness: Many allergists recommend that patients receiving immunotherapy carry a personal epinephrine auto-injector (e.g., EpiPen) to treat potential delayed reactions.

• Symptom Tracking: Patients should keep a log of any local or systemic reactions.
• Peak Flow Monitoring: For asthmatic patients, peak flow may be measured before each injection to ensure lung function is stable.
• Periodic Re-testing: Every 2-3 years, the healthcare provider may perform repeat skin testing to assess the progress of desensitization.

Ornithogalum Umbellatum Whole does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

Alcohol consumption should be avoided on the day of an injection. Alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the speed of allergen absorption and heighten the risk or severity of an allergic reaction.

Immunotherapy is typically a 3-to-5-year commitment. Stopping prematurely usually results in the return of allergy symptoms. There is no 'withdrawal' syndrome associated with stopping Ornithogalum Umbellatum Whole, as it is not a physically addictive substance; however, the immune system will eventually revert to its allergic state without the maintenance stimulus.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ornithogalum Umbellatum Whole. Ensure they are aware of any heart conditions or lung diseases.

• Beta-Blockers (Non-selective and Selective): Drugs like propranolol, metoprolol, or atenolol are generally contraindicated in patients receiving potent allergenic extracts. Clinical Consequence: Beta-blockers can increase the severity of an anaphylactic reaction and, more importantly, can render epinephrine (the primary treatment for anaphylaxis) ineffective. This creates a life-threatening situation where a reaction cannot be easily reversed.

• ACE Inhibitors: Medications used for blood pressure (e.g., lisinopril, enalapril). Clinical Consequence: There is some evidence that ACE inhibitors may increase the risk of more severe systemic reactions to immunotherapy, possibly by interfering with the body's ability to degrade bradykinin.
• MAO Inhibitors: Antidepressants like phenelzine or selegiline. Clinical Consequence: These can potentiate the effects of epinephrine, leading to dangerous spikes in blood pressure if a reaction occurs and needs treatment.

• Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), or diphenhydramine (Benadryl). Clinical Consequence: These drugs will suppress the 'wheal-and-flare' response during diagnostic skin testing, leading to false-negative results. Management: Patients must stop taking most antihistamines for 3 to 7 days before skin testing.
• Tricyclic Antidepressants (TCAs): Like amitriptyline. Clinical Consequence: Similar to MAOIs, these can affect the body's response to epinephrine.

• Large Meals: It is generally advised not to eat a very large or heavy meal immediately before or after an injection, as this can affect blood flow and absorption rates.
• Alcohol: As mentioned, alcohol can increase the risk of a systemic reaction through vasodilation.

• St. John's Wort: While not a direct interaction with the extract, it can interact with many emergency medications used to treat reactions.
• High-Dose Vitamin C: Some studies suggest very high doses of Vitamin C may have a mild antihistamine effect, which could theoretically interfere with diagnostic skin test accuracy.

• Total IgE Levels: Immunotherapy can cause a transient rise in total serum IgE levels followed by a long-term decline.
• Specific IgE (RAST/ImmunoCAP): Levels of IgE specific to Ornithogalum Umbellatum may decrease over years of treatment, while specific IgG4 levels will increase.

For each major interaction, the primary concern is not the extract itself, but the safety of the patient should an emergency occur. The management strategy is usually to switch to alternative blood pressure or depression medications that do not interfere with epinephrine.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including eye drops (which can contain beta-blockers).

• Severe or Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) of less than 80% of their predicted value or those with frequent acute exacerbations are at an unacceptably high risk for fatal anaphylaxis. The mechanism is that the lungs are already compromised and cannot withstand the bronchospasm associated with a systemic reaction.
• Recent Myocardial Infarction or Unstable Angina: Patients with significant cardiovascular disease may not be able to tolerate the stress of a systemic reaction or the side effects of the epinephrine required to treat it.
• History of Severe Reaction to Immunotherapy: If a patient has previously experienced life-threatening anaphylaxis to Ornithogalum Umbellatum Whole despite dosage adjustments, further treatment is contraindicated.

• Autoimmune Diseases: Conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis require a careful risk-benefit analysis, as immunotherapy could theoretically stimulate the immune system in a way that worsens the underlying autoimmune condition.
• Malignancy: Patients with active cancer are generally not started on immunotherapy, as the immune system is already under significant stress.
• Beta-Blocker Therapy: While often considered an absolute contraindication by many clinics, it is sometimes a relative contraindication if the patient can be switched to another class of antihypertensive medication.

Ornithogalum Umbellatum is part of the Asparagaceae family. Patients who are highly allergic to other members of this family (such as Asparagus, Hyacinths, or Lily of the Valley) may exhibit cross-reactivity. This means they may react more strongly to the Ornithogalum Umbellatum Whole extract than expected based on their exposure history.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or severe anxiety regarding needles, before prescribing Ornithogalum Umbellatum Whole.

• FDA Category: Generally classified as Category C.
• Risk Summary: There are no adequate and well-controlled studies of Ornithogalum Umbellatum Whole in pregnant women. The primary risk during pregnancy is not the extract itself, but the potential for maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen) and lead to miscarriage or fetal brain damage.
• Clinical Practice: It is standard practice not to start new immunotherapy during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the healthcare provider may choose to continue the treatment at the same or a slightly reduced dose.

• Risk Summary: It is not known if the protein components of Ornithogalum Umbellatum Whole are excreted in human milk. However, since these are large proteins that are digested in the infant's gut, the risk to a nursing infant is considered negligible. Immunotherapy is generally considered safe for breastfeeding mothers.

• Approved Age: Immunotherapy is typically not started in children under age 5 because of the difficulty in communicating symptoms of an impending systemic reaction.
• Considerations: Children have a higher risk of 'late-phase' reactions. Dosing must be meticulous. Parents must be trained to recognize signs of anaphylaxis in children, which may include sudden changes in behavior, irritability, or 'clinging' behavior.

• Risk Profile: Patients over 65 are at a higher risk for complications from systemic reactions due to the increased likelihood of underlying heart or lung disease.
• Pharmacokinetics: While the metabolism of the proteins doesn't change significantly, the physiological reserve to handle a 'medical emergency' is lower. Providers often use a more conservative dosing schedule for older adults.

No dosage adjustments are required. The proteins are broken down into amino acids. However, if the patient is on dialysis, the timing of the injection should be discussed with the nephrologist to ensure hemodynamic stability.

No adjustments are necessary as the liver's CYP450 system is not involved in the clearance of allergenic proteins.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant during the course of your treatment.

Ornithogalum Umbellatum Whole acts as an immunomodulator. The primary molecular mechanism involves the presentation of plant-derived antigens (proteins) by dendritic cells to naive T-cells. In an allergic individual, this usually results in a Th2 response. By providing a consistent, low-level exposure via subcutaneous injection, the extract induces the development of T-regulatory (Treg) cells. These Treg cells produce Interleukin-10 (IL-10), which has several effects:

1. 1It suppresses the production of IgE by B-cells.
2. 2It induces B-cells to produce IgG4 (blocking antibodies).
3. 3It reduces the recruitment and activation of eosinophils and mast cells in the tissues.

• Dose-Response: There is a clear dose-response relationship; higher doses (within the maintenance range) are generally more effective at inducing long-term tolerance than lower doses.
• Onset of Effect: Diagnostic skin test results are visible within 15-20 minutes. Therapeutic effects (symptom reduction) typically take 3 to 6 months to become noticeable.
• Duration: The effects of a successful 3-to-5-year course of immunotherapy can last for many years after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous) |

| Protein Binding | N/A |

| Half-life | Hours (Proteins) |

| Tmax | 1-2 hours (Systemic absorption) |

| Metabolism | Proteolysis |

| Excretion | Renal (as amino acids/peptides) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides extracted from the whole Ornithogalum umbellatum plant.
• Solubility: Soluble in aqueous solutions (saline, buffered saline).
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic proteins.

Ornithogalum Umbellatum Whole is a Non-Standardized Plant Allergenic Extract. It is grouped with other weed and flower extracts like Dandelion, Goldenrod, and Daisy extracts used in clinical allergy practice.